Logo

AstraZeneca's Forxiga (dapagliflozin) Receives CHMP's Recommendation for Approval to Treat Chronic Kidney Disease in EU

Share this

AstraZeneca's Forxiga (dapagliflozin) Receives CHMP's Recommendation for Approval to Treat Chronic Kidney Disease in EU

Shots:

  • The CHMP’s opinion is based on P-III DAPA-CKD trial evaluating the efficacy of Forxiga (10mg- qd in addition to SoC) vs PBO in 4304 patients with CKD Stage 2-4 and elevated urinary albumin excretion- with & without T2D
  • Results: reduction in risk of the composite of worsening of renal function- ESKD- CV or renal death- safety & tolerability were consistent with the well-established safety profile of Forxiga
  • The therapy is recently approved in the US for CKD in adults with & without T2D & is currently under review in Japan & other countries globally. The therapy is indicated as an adjunct to diet & exercise to improve glycemic control in adults with T2D & for HF with HFrEF

Ref: AstraZeneca | Image: The Scientist Magazine

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions